過敏性腸症候群（Irritable Bowel Syndrome）治療薬の世界市場予測および分析...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要（一部）】

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 14
1.2 List of Figures 18
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 22
3.2 Classification 22
3.3 Symptoms 23
3.4 Prognosis 23
3.5 Quality of Life 24
4 Epidemiology 25
4.1 Disease Background 25
4.2 Risk Factors and Comorbidities 26
4.3 Global Trends 27
4.3.1 US 29
4.3.2 5EU 31
4.3.3 Japan 31
4.4 Forecast Methodology 32
4.4.1 Sources Used 32
4.4.2 Sources Not Used 38
4.4.3 Forecast Assumptions and Methods – Total Prevalent Cases of IBS 39
4.4.4 Forecast Assumptions and Methods – IBS Subtype Segmentations 42
4.5 Epidemiological Forecast for IBS (2013-2023) 44
4.5.1 Total Prevalent Cases of IBS 44
4.5.2 Age-Specific Total Prevalent Cases of IBS 46
4.5.3 Sex-Specific Total Prevalent Cases of IBS 48
4.5.4 Age-Standardized Total Prevalence of IBS 50
4.5.5 Total Prevalent Cases of IBS by Clinical Subtype 51
4.6 Discussion 53
4.6.1 Epidemiological Forecast Insight 53
4.6.2 Limitations of the Analysis 54
4.6.3 Strengths of the Analysis 56
5 Disease Management 57
5.1 Diagnosis and Treatment Overview 57
5.1.1 Diagnosis 57
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 59
5.1.3 Clinical Practice 62
5.2 US 64
5.3 France 66
5.4 Germany 68
5.5 Italy 70
5.6 Spain 72
5.7 UK 74
5.8 Japan 76
6 Competitive Assessment 78
6.1 Overview 78
6.2 Product Profiles – Major Brands, IBS-C 79
6.2.1 Amitiza (lubiprostone) 79
6.2.2 Linzess (linaclotide) 85
6.3 Product Profiles – Major Brands, IBS-D 93
6.3.1 Lotronex (alosetron) 93
6.3.2 Irribow (ramosetron) 98
6.4 Product Profiles – Major Brands, Other 103
6.4.1 Antidepressants 103
6.5 Other Therapeutic Classes 108
7 Unmet Need and Opportunity 110
7.1 Overview 110
7.2 More Effective Pharmacotherapies 111
7.2.1 Unmet Need 111
7.2.2 Gap Analysis 112
7.2.3 Opportunity 113
7.3 Therapies for the IBS-D Subtype 113
7.3.1 Unmet Need 113
7.3.2 Gap Analysis 114
7.3.3 Opportunity 114
7.4 Therapies for the IBS-M Subtype 114
7.4.1 Unmet Need 114
7.4.2 Gap Analysis 115
7.4.3 Opportunity 115
7.5 Therapies to Address Abdominal Pain and Bloating Symptoms 115
7.5.1 Unmet Need 115
7.5.2 Gap Analysis 116
7.5.3 Opportunity 116
7.6 Improved Diagnosis Rate for IBS 117
7.6.1 Unmet Need 117
7.6.2 Gap Analysis 117
7.6.3 Opportunity 117
8 Pipeline Assessment 119
8.1 Overview 119
8.2 Clinical Trial Mapping 119
8.2.1 Clinical Trials by Therapy Type 119
8.3 Promising Drugs in Clinical Development 120
8.4 Product Profiles – Late-Stage Pipeline, IBS-D 123
8.4.1 Eluxadoline 123
8.4.2 Ibodutant (MEN-15596) 130
8.4.3 Xifaxan (rifaximin) 136
8.5 Product Profiles – Late-Stage Pipeline, IBS-C 145
8.5.1 Plecanatide 145
8.5.2 Tenapanor (AZD1722, RDX5791) 151
8.6 Other Drugs in Development for IBS 156
9 Current and Future Players 157
9.1 Overview 157
9.2 Trends in Corporate Strategy 159
9.3 Company Profiles 160
9.3.1 Actavis 160
9.3.2 Astellas 162
9.3.3 Almirall 165
9.3.4 Ironwood 166
9.3.5 Takeda 169
9.3.6 Sucampo 171
9.3.7 Prometheus 173
9.3.8 Salix 175
9.3.9 Menarini 177
9.3.10 Synergy 179
9.3.11 AstraZeneca 181
10 Market Outlook 183
10.1 Global Markets 183
10.1.1 Forecast 183
10.1.2 Drivers and Barriers – Global Issues 187
10.2 US 188
10.2.1 Forecast 188
10.2.2 Key Events 192
10.2.3 Drivers and Barriers 192
10.3 France 194
10.3.1 Forecast 194
10.3.2 Key Events 198
10.3.3 Drivers and Barriers 198
10.4 Germany 200
10.4.1 Forecast 200
10.4.2 Key Events 204
10.4.3 Drivers and Barriers 204
10.5 Italy 206
10.5.1 Forecast 206
10.5.2 Key Events 210
10.5.3 Drivers and Barriers 210
10.6 Spain 212
10.6.1 Forecast 212
10.6.2 Key Events 215
10.6.3 Drivers and Barriers 215
10.7 UK 217
10.7.1 Forecast 217
10.7.2 Key Events 221
10.7.3 Drivers and Barriers 221
10.8 Japan 223
10.8.1 Forecast 223
10.8.2 Key Events 227
10.8.3 Drivers and Barriers 227
11 Appendix 230
11.1 Bibliography 230
11.2 Abbreviations 240
11.3 Methodology 243
11.4 Forecasting Methodology 243
11.4.1 Diagnosed IBS Patients 243
11.4.2 Drugs Included in Each Therapy Type 244
11.4.3 Launch and Patent Expiry Dates 244
11.4.4 General Pricing Assumptions 245
11.4.5 Individual Drug Assumptions 246
11.4.6 Generic Erosion 247
11.4.7 Pricing of Pipeline Agents 247
11.5 Primary Research – KOLs Interviewed for This Report 248
11.6 Primary Research – Prescriber Survey 250
11.7 About the Authors 251
11.7.1 Analyst 251
11.7.2 Therapy Area Director 251
11.7.3 Epidemiologist 252
11.7.4 Global Head of Healthcare 253
11.8 About GlobalData 254
11.9 Disclaimer 254

【レポート販売概要】

■ タイトル：過敏性腸症候群（Irritable Bowel Syndrome）治療薬の世界市場予測および分析
■ 英文：PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023
■ 発行日：2014年12月31日
■ 調査会社：GlobalData
■ 商品コード：GDHC97PIDR
■ 調査対象地域：グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業（メーカー、ベンダー）、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。

Follow:

RSS [PRニュース]